Positioning
A New Force of China’s National Pharmaceutical Industry
Serving as a premier platform for the R&D and manufacturing of advanced sustained and controlled-release formulations, the Company specializes in osmotic pumps, coated pellets, and matrix tablets. We have successfully passed multiple U.S. FDA cGMP on-site inspections, achieving "zero-defect" status on two occasions. Furthermore, our facilities enable synchronized manufacturing for both the Chinese and U.S. markets, ensuring simultaneous registration and sales in both regions.
Qingdao Baheal Pharmaceutical Co., Ltd. ( "Qingdao Baheal Pharmaceutical"), formerly known as Qingdao No. 2 Pharmaceutical Factory, boasts a history of over 60 years. As a subsidiary of the listed company Baheal Pharmaceutical Co., Ltd. (SZ. 301015), it is located at No. 88 Taiji Road, Jimo District, Qingdao, occupying a total land area of approximately 128 mu (85,600 square meters).
The Company distinguishes itself as the first pharmaceutical formulation enterprise in Qingdao to pass a U.S. FDA inspection. It has garnered numerous accolades, including "Shandong Gazelle Enterprise," "National High-tech Enterprise," "Qingdao Innovative Small and Medium-sized Enterprise," and "Qingdao Specialized, Refined, Distinctive, and Innovative Innovative Small and Medium-sized Enterprise(SME)." Additionally, it received the ISPE Best Facility Management Award and was designated as both the "Qingdao Technology Innovation Center for Sustained and Controlled-release Solid Preparations" and the "Jimo Engineering Technology Research Center for Sustained and Controlled-release Solid Preparations." Furthermore, the Company has achieved certification for the Management System for the Integration of Informatization and Industrialization and has been recognized as a "Qingdao Digital Workshop for High-end Sustained and Controlled-release Preparations."
Multiple products developed by the Company have been awarded grants under prestigious initiatives, including the National Science and Technology Major Project for "Major New Drug Development" of the 13th Five-Year Plan, the Major Scientific and Technological Innovation Project of the Shandong Provincial Department of Science and Technology, and the Key Special Project for Independent Innovation under the Qingdao Science and Technology Program.
Going forward, Qingdao Baheal Pharmaceutical remains committed to deepening its expertise in the field of high-end sustained and controlled-release formulations. Driven by technological innovation, we will continue to develop and optimize novel products tailored to diverse clinical needs, delivering international-quality pharmaceutical formulations to patients both at home and abroad.
+year
production experience
㎡
covers an area of
+item
for letters patent are
+
Number of cooperative customers
Baheal Pharma is an innovative pharmaceutical company specializing in the research and development of modernized traditional Chinese medicineand and slow-released formulations. It is a subsidiary of Baheal Pharma Group (SZ. 301015). Adhering to the principle of "international quality, protect health", the company takes independent research and development as its core, modern medical theory as its guidance, and high-end sustained-release formulation technology as its characteristic, to create innovative Chinese traditional medicine and chemical medicine products with independent intellectual property rights.
In the field of modern traditional Chinese medicine production, based on the concept of disease diagnosis, quality control, and proven efficacy, Baheal Pharma has built a complete modern industrial chain of traditional Chinese medicine from medicinal herb planting, extraction to finished product formulation and commercialization. It has more than 10 self owned traditional Chinese medicine planting bases in 8 provinces, and has established DNA and fingerprint archives and traceable information systems for original medicinal herbs, creating an international standard modern compound Chinese medicine production platform. In the field of chemical drug production, the company focuses on high-end formulation technologies with high barriers such as research and development of osmotic pump controlled release dosage forms. The related research and development has been selected for the national "13th Five Year Plan Major New Drug Creation Science and Technology Special Project". The production platform has repeatedly passed the cGMP on-site inspection of the US FDA with "zero defects", and the products have achieved co-production and sales in China and the United States.
The company has achieved innovative breakthroughs in multiple treatment fields such as liver disease and metabolic diseases, and has established an international, standardized, and modern R&D and production system for traditional Chinese and chemical medicine. With two major R&D production bases in Shanghai and Qingdao, the company can provide one-stop CMO services from pharmaceutical research, process development, registration and application to production and commercialization.
To better serve human health, Baheal Pharma is partnering with national research institutions to establish a research cooperation platform, focusing on breakthroughs in the treatment of difficult diseases and continuously providing international quality drugs to global consumers.
A New Force of China’s National Pharmaceutical Industry
Through technological innovation, we continuously develop and optimize innovative products tailored to clinical needs, delivering greater health value to patients and ensuring a high quality of life for our employees."
Bodhi Attain Health
People-oriented, respect for sciences, accountable, open minded and collaborative, perseverant and confident.
Technological Innovation,Quality First,Continuous Improvement, Safety & Efficacy,Integrity & Pragmatism,Customer Satisfaction(Customer Centricity)
We can succeed because we are united, we are diligent, we constantly reflect on ourselves!